Products for Research Use Only

WDR5-IN-4

CAT: 0804-HY-111753-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-111753-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
WDR5-IN-4 (Compound C6) is a WIN site inhibitor of chromatin-associated WD repeat domain 5 protein (WDR5), Kd The value is 0.1 nM. WDR5-IN-4 is able to displace WDR5 from chromatin and reduce the expression of related genes, causing translation inhibition and nucleolar stress. Has anti-cancer effects [1][1].
CAS Number
2407457-36-5
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Apoptosis; WDR5
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/WIN_site_inhibitor_1.html
Purity
98.13
Solubility
10 mM in DMSO
Smiles
ClC1=CC=C(CNC(C2=CC(CN3C(N(C)C=C3)=N)=CC(C4=C(C)N=C(F)C=C4)=C2)=O)C=C1Cl
Molecular Formula
C25H22Cl2FN5O
Molecular Weight
498.38
Precautions
H315, H319, H335
References & Citations
[1]Aho ER, et al. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Cell Rep. 2019 Mar 12;26 (11) :2916-2928.e13.|[2]Wang H, et al. The E3 ubiquitin ligase RNF220 maintains hindbrain Hox expression patterns through regulation of WDR5 stability[J]. Elife, 2024, 13: RP94657.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Cell Rep. 2023 Apr 21;42 (5) :112423.|bioRxiv. 2023 Dec 16.|bioRxiv. 2023 Jun 5.